2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Pancreatic Neoplasms
3
Neoplasms
2
Disease
2
Spinal Cord Neoplasms
1
Rectal Neoplasms
1
Pleural Effusion
1
Pleural Diseases
1
Pituitary Neoplasms
1
Parkinson Disease
1
Pancreatitis, Chronic
1
Pancreatic carcinoma, familial
1
Nervous System Diseases
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Mesothelioma
1
Hereditary pancreatitis
1
Hematologic Diseases
1
Epilepsy
1
Diabetes Mellitus
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cardiotoxicity
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Bone Marrow Diseases
1
Interventions
Brentuximab Vedotin
21
Cyclophosphamide
20
fludarabine
16
Rituximab
13
Lenalidomide
13
Dexamethasone
12
fludarabine phosphate
10
Melphalan
10
Busulfan
10
Mycophenolic Acid
9
pirtobrutinib
7
dacetuzumab
7
Whole-Body Irradiation
7
Tacrolimus
7
Bortezomib
7
Doxorubicin
6
Azacitidine
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Imatinib Mesylate
5
Bone Marrow Transplantation
5
ponatinib
4
pomalidomide
4
Mesna
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Blood Specimen Collection
4
Bendamustine Hydrochloride
4
venetoclax
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
Clinical Laboratory Techniques
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled